A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease: Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study -- Krucoff et al. 51 (16): 1543 Figure IG1 -- Journal of the American College of Cardiology

Advertisement


		Search


	Submit Manuscripts
	Author Information
	Subscribe/Renew
	Order Reprints
	Email Alerts
	Feedback
	RSS Feed
	CME


	About the Journal
	Editorial Board & Staff


	About JACC CME
	Hardware/Software Requirements
	Contact Us
	Policy on Privacy and Confidentiality
	Copyright Information


Still not a subscriber to JACC Imaging or JACC Interventions? Click here to sign up now!


	ACC.org
	Cardiosmart
	Cardiosource
	CVN
	Imaging Library
	JACC Imaging
	JACC Interventions

2009 Focused Updates: ACC/AHA Guidelines for STEMI and ACC/AHA/SCAI Guidelines for PCI

2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery

ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research

	Help viewing high resolution images
	Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.

Figure 1 The CoStar Stent

The CoStar stent reservoir technology at 7 days and at 6 months.

Return to article

Advertisement